Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
Background: Patients with severe alopecia areata (AA), including alopecia totalis (AT) and alopecia universalis (AU), are usually resistant to treatment. While tofacitinib is emerging as a promising therapy for severe AA, little is known about its efficacy and safety in Asians. Objectives: To evalua...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Dermatologica Sinica |
Subjects: | |
Online Access: | http://www.dermsinica.org/article.asp?issn=1027-8117;year=2020;volume=38;issue=1;spage=3;epage=8;aulast=Dai |
id |
doaj-fb771b1eb48c4f00a0eef1df41700dd5 |
---|---|
record_format |
Article |
spelling |
doaj-fb771b1eb48c4f00a0eef1df41700dd52020-11-25T02:50:34ZengWolters Kluwer Medknow PublicationsDermatologica Sinica1027-81172223-330X2020-01-013813810.4103/ds.ds_26_19Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areataYing-Xiu DaiChen-Pu YehChih-Chiang ChenBackground: Patients with severe alopecia areata (AA), including alopecia totalis (AT) and alopecia universalis (AU), are usually resistant to treatment. While tofacitinib is emerging as a promising therapy for severe AA, little is known about its efficacy and safety in Asians. Objectives: To evaluate the efficacy and safety of tofacitinib for treating severe AA. Methods: We included patients with ≥50% scalp hair loss, disease for ≥6 months, and tofacitinib therapy for ≥4 months. The efficacy, evaluated based on the percent change in severity of alopecia tool (SALT) score, and response time, defined as time from baseline to reach >50% improvement in SALT score, were assessed. Results: We included 35 patients (21 with AA, 3 with AT, and 11 with AU). There were 18 men and 17 women (median age: 39 [range: 12–68] years). After 4–24 months of treatment, 74.3% showed clinical response, with 51.4% of the patients achieving ≥50% hair regrowth. Patients with AA showed higher percent change in SALT score than patients with AT/AU (median [interquartile range]: 60.7% [0–98.2] vs. 41.1% [8.9–98.7], P = 0.047). Initial SALT score was negatively associated with the latest percent change in SALT score (P = 0.025). Duration of disease and current episode were positively associated with response time to tofacitinib (P = 0.018 and 0.026, respectively). Patients tolerated tofacitinib well without serious adverse events. Conclusion: Tofacitinib effectively promoted hair regrowth in Asian patients with severe AA. Randomized controlled trials with larger sample size are needed to confirm the long-term efficacy and safety of tofacitinib for treating severe AA.http://www.dermsinica.org/article.asp?issn=1027-8117;year=2020;volume=38;issue=1;spage=3;epage=8;aulast=Daialopecia areatajanus kinase inhibitortofacitinibtreatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ying-Xiu Dai Chen-Pu Yeh Chih-Chiang Chen |
spellingShingle |
Ying-Xiu Dai Chen-Pu Yeh Chih-Chiang Chen Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata Dermatologica Sinica alopecia areata janus kinase inhibitor tofacitinib treatment |
author_facet |
Ying-Xiu Dai Chen-Pu Yeh Chih-Chiang Chen |
author_sort |
Ying-Xiu Dai |
title |
Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata |
title_short |
Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata |
title_full |
Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata |
title_fullStr |
Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata |
title_full_unstemmed |
Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata |
title_sort |
efficacy and safety of tofacitinib therapy in asian patients with severe alopecia areata |
publisher |
Wolters Kluwer Medknow Publications |
series |
Dermatologica Sinica |
issn |
1027-8117 2223-330X |
publishDate |
2020-01-01 |
description |
Background: Patients with severe alopecia areata (AA), including alopecia totalis (AT) and alopecia universalis (AU), are usually resistant to treatment. While tofacitinib is emerging as a promising therapy for severe AA, little is known about its efficacy and safety in Asians. Objectives: To evaluate the efficacy and safety of tofacitinib for treating severe AA. Methods: We included patients with ≥50% scalp hair loss, disease for ≥6 months, and tofacitinib therapy for ≥4 months. The efficacy, evaluated based on the percent change in severity of alopecia tool (SALT) score, and response time, defined as time from baseline to reach >50% improvement in SALT score, were assessed. Results: We included 35 patients (21 with AA, 3 with AT, and 11 with AU). There were 18 men and 17 women (median age: 39 [range: 12–68] years). After 4–24 months of treatment, 74.3% showed clinical response, with 51.4% of the patients achieving ≥50% hair regrowth. Patients with AA showed higher percent change in SALT score than patients with AT/AU (median [interquartile range]: 60.7% [0–98.2] vs. 41.1% [8.9–98.7], P = 0.047). Initial SALT score was negatively associated with the latest percent change in SALT score (P = 0.025). Duration of disease and current episode were positively associated with response time to tofacitinib (P = 0.018 and 0.026, respectively). Patients tolerated tofacitinib well without serious adverse events. Conclusion: Tofacitinib effectively promoted hair regrowth in Asian patients with severe AA. Randomized controlled trials with larger sample size are needed to confirm the long-term efficacy and safety of tofacitinib for treating severe AA. |
topic |
alopecia areata janus kinase inhibitor tofacitinib treatment |
url |
http://www.dermsinica.org/article.asp?issn=1027-8117;year=2020;volume=38;issue=1;spage=3;epage=8;aulast=Dai |
work_keys_str_mv |
AT yingxiudai efficacyandsafetyoftofacitinibtherapyinasianpatientswithseverealopeciaareata AT chenpuyeh efficacyandsafetyoftofacitinibtherapyinasianpatientswithseverealopeciaareata AT chihchiangchen efficacyandsafetyoftofacitinibtherapyinasianpatientswithseverealopeciaareata |
_version_ |
1724737821174923264 |